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Abstract
Background
Recent pertussis outbreaks have prompted re-examination of post-exposure prophylaxis
(PEP) strategies, when immunization is not immediately protective. Chemoprophylaxis is
recommended to household contacts; however there are concerns of clinical failure and
significant adverse events, especially with erythromycin among infants who have the high-
est disease burden. Newer macrolides offer fewer side effects at higher drug costs. We
sought to determine the cost-effectiveness of PEP strategies from the health care payer
perspective.
Methods
AMarkov model was constructed to examine 4 mutually exclusive strategies: erythromycin,
azithromycin, clarithromycin, or no intervention, stratified by age group of contacts (“infant”,
“child”, and “adult”). Transition probabilities, costs and quality-adjusted life years (QALYs)
were derived from the literature. Chronic neurologic sequelae were modeled over a lifetime,
with costs and QALYs discounted at 5%. Associated health outcomes and costs were com-
pared, and incremental cost-effectiveness ratios (ICER) were calculated in 2012 Canadian
dollars. Deterministic and probabilistic sensitivity analyses were performed to evaluate the
degree of uncertainty in the results.
Findings
Azithromycin offered the highest QALYs in all scenarios. While this was the dominant strate-
gy among infants, it produced an ICER of $16,963 per QALY among children and $2,415
per QALY among adults. Total QALYs with azithromycin were 19.7 for a 5-kg infant, 19.4 for
a 10-year-old child, and 18.8 for a 30-year-old adult. The costs of azithromycin PEP among
infants, children and adults were $1,976, $132 and $90, respectively. While results were
sensitive to changes in PEP effectiveness (11% to 87%), disease transmission (variable
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among age groups) and hospitalization costs ($379 to $59,644), the choice of strategy
remained unchanged.
Interpretation
Pertussis PEP is a cost-effective strategy compared with no intervention and plays an im-
portant role in contact management, potentially in outbreak situations. From a healthcare
payer perspective, azithromycin is the optimal strategy among all contact groups.
Introduction
In the pre-vaccine era, pertussis was a major childhood illness affecting children primarily
under 10 years of age, and a major cause of death among infants under 1 year [1]. Caused by
Bordetella pertussis, the disease was pandemic throughout the 20th century, with cyclical epi-
demic peaks every 2 to 5 years [1]. Widespread immunization of children has not lengthened
the epidemic cycle as much as expected [2], suggesting that adults serve as a reservoir for dis-
ease in young children [3]; pertussis is common and endemic among this group [4,5].
Prolonged pertussis outbreaks have recently been reported across North America [6–9],
prompting re-examination of control and prevention strategies [10]. In 2010, 101 cases of pertus-
sis were reported in Ontario (0.8 cases per 100,000 population) [6]. Following a 2011–2012 out-
break, 792 cases were reported across both years, or 5.9 per 100,000 population. Immunization
coverage in Ontario among 7- and 17-year olds in 2012 was 76% and 68%, respectively [6].
The resurgence of pertussis has been attributed to waning immunity in older children and
poor vaccine efficacy against other Bordetella species associated with pertussis-like illnesses
[7,11,12]. A randomized, controlled trial (RCT) of post-exposure prophylaxis (PEP) with
erythromycin compared with placebo found PEP to be effective in preventing secondary cases
in 67.5% of adult and pediatric household contacts [13]. Practice guidelines in Canada, the
United States and the United Kingdom recommend chemoprophylaxis with a macrolide for
household and close contacts of pertussis cases of all ages, irrespective of immunization status
[14–16]. While studies have examined erythromycin as a treatment and PEP agent, the newer
macrolides, azithromycin and clarithromycin, have also been shown to be active against B. per-
tussis in vitro [17], and have been recommended as better-tolerated, equally effective [18,19]
but more costly treatment options [15,16].
Economic evaluations can provide “value-for-money” information to support health care
decision-making [20]. A cost-utility analysis was performed to compare the additional cost per
QALY gained across the 4 strategies of erythromycin, azithromycin, clarithromycin and no
prophylaxis, with an aim to estimate the effects, costs and cost-effectiveness of alternative strat-
egies for the prevention of pertussis among household contacts. This analysis is especially time-
ly in informing clinical practice and health care resource allocation given the recent outbreaks
among under-immunized populations in countries that have well-established immunization
programs.
Methods
Cost-utility analysis
In accordance with established guidelines for economic evaluations [20,21], a cost-utility analy-
sis was performed to determine whether PEP with a macrolide was cost-effective compared to
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no PEP (i.e. treatment of cases as they arise) in household contacts exposed to pertussis. Specif-
ic PEP regimens considered were erythromycin and azithromycin in all age groups (infants,
children and adults) and clarithromycin in children and adults only. The primary outcome was
the incremental cost-effectiveness ratio (ICER), derived from estimated quality-adjusted life
years (QALYs) and direct healthcare cost over a lifetime time horizon. The analysis was con-
ducted from the healthcare payer perspective (i.e. Ontario’s Ministry of Health and Long-Term
Care), with a commonly-used cost-effectiveness threshold of $50,000 per QALY gained [22].
Healthcare costs for PEP and the treatment of cases are included. All costs were expressed in
2012 Canadian dollars (1 US dollar was 0.99958 Canadian dollars) [23–26]. Costs and health
outcomes were discounted at 5% per year as recommended for health economic evaluations in
Canada [20].
Model and assumptions
AMarkov model was constructed to evaluate the lifetime health outcomes and costs of devel-
oping pertussis among household contacts following expectant management or PEP. Most
events occurred in the first year. The Markov model had a cycle length of 1 year and incorpo-
rated 2 health states: survival and death. The duration of acute events in the first year was taken
into account. Household contacts were stratified into 3 age groups: less than 1 year of age
(“infant”), 1 to 12 years old (“child”) and greater than 12 years old (“adult”).
The model structure was the same for all contacts (Fig. 1A and B). Infant contacts had a
higher frequency of hospitalization for severe disease, including significant respiratory or neu-
rologic complications. Children and adult contacts with respiratory symptoms were managed
in the outpatient setting depending on severity, although all patients with neurologic presenta-
tions required hospitalization. Household contacts that developed mild symptoms went to
their general practitioner (GP) rather than an emergency department. Mild-to-moderate
cough resulted in an additional GP visit and antibiotics, and those with severe cough or pneu-
monia had 2 additional GP visits, antibiotics and a chest x-ray. Survivors of respiratory disease
requiring hospitalization did not experience long-term sequelae. In all groups, pertussis-related
deaths were assumed to occur during hospitalization. Age-specific mortality was obtained
from Statistics Canada [27]. Given that the total duration of illness is 6–8 weeks [1], all costs at-
tributable to pertussis were assumed to have been incurred in the first year unless patients ex-
perienced neurological sequelae, which were assumed to require lifetime healthcare services.
Data
Probabilities of disease-specific outcomes and medication-related gastrointestinal effects were
drawn from RCTs and observational cohort studies. All data are shown in Table 1. Secondary
attack rates of pertussis are highest among young infants at 65% [28], with a 10-fold decrease
among children and adults [13]. Similarly, more than two-thirds of infants with pertussis are
managed in hospital [29], compared to only 7% of children [30] and 3.5% of adult contacts
[29]. Encephalitis is an infrequent but serious complication of pertussis, affecting 0.5% infants
[31], 0.08% children [30] and 0.05% adults who are hospitalized [30]. Early economic evalua-
tions and population studies reported residual effects in one-third of survivors of pertussis en-
cephalitis [1,32,33]. Death is least likely to occur among adult patients with pertussis, at 0.01%,
followed by children at 0.06%. The probability of death is highest among infants, at 0.6% [29].
Intervention
An RCT of erythromycin prophylaxis against pertussis demonstrated 67.5% effectiveness (95%
CI 7.6% to 88.7%) in preventing culture-positive pertussis among household contacts [13].
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With no subsequent studies re-examining this intervention, this point estimate of effectiveness
was extrapolated to azithromycin and clarithromycin based on their comparatively similar effi-
cacy with erythromycin in treatment studies [18,19] which is in keeping with current pertussis
PEP guidelines [15,16]. PEP was assumed to have been given within 21 days of onset of cough
in the index case and before a secondary case had occurred [28]. Clarithromycin has not been
studied for those under 1 month of age and so was not included as an option for the infant
group [19].
All contacts who receive an antibiotic have a likelihood of developing a gastrointestinal ad-
verse event. These probabilities were derived from case series and clinical trials involving eryth-
romycin, clarithromycin and/or azithromycin. Neonates may be more than 10 times at risk for
infantile hypertrophic pyloric stenosis (IHPS) in the month following orally administered
erythromycin, compared to unexposed neonates, with a peak incidence of 1.28% in under
3 month olds [34,35]. As the risk of IHPS with erythromycin has had an impact on recommen-
dations for infant PEP, this was explicitly examined in the model. There were 2 case reports of
azithromycin-associated IHPS [36]. With over 4,000 cases noted over a 10-year period in the
US [29] and azithromycin having been adopted as the preferred agent for young infants [16], a
Fig 1. Markovmodel for post-exposure prophylaxis strategy. The square represents a decision node, and circle represents a chance node. The triangle
represents the final outcome for that event pathway. Consequences associated with the chance node are mutually exclusive. PEP: post-exposure
prophylaxis; GI: gastrointestinal.
doi:10.1371/journal.pone.0119271.g001
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point estimate of 0.05%, or 2 cases among 4,000 infants treated with azithromycin, was
assumed.
If no PEP was received, or no gastrointestinal event occurred on chemoprophylaxis, then
erythromycin was used for treatment of pertussis as the least expensive option [37]. If IHPS oc-
curred during erythromycin PEP, infants who subsequently developed pertussis received azi-
thromycin for treatment [16]. However, if IHPS followed azithromycin PEP, then infants with
subsequent pertussis were treated with erythromycin. As azithromycin and clarithromycin
have fewer side effects than erythromycin, child and adult contacts that developed pertussis
after experiencing PEP-related side effects were treated with either of these agents.
Table 1. Event probabilities for decision model.
Contact group Parameter Base case value Range examined References
ALL Prophylaxis effectiveness 0.675 0.076–0.887 [13]
INFANT
Intervention IHPS following erythromycin 0.0128 0.0026–0.0275 [35]
IHPS following azithromycin 0.0005 0.0001–0.0010 Assumption1
Pertussis Develops pertussis post-exposure 0.65 0.25–0.81 [28,70]
Hospitalization for severe disease 0.69 0.59–0.82 [29,30]
Develops complication in hospital 0.14 0.10–0.19 [42,66]
Death 0.006 0.001–0.009 [29,66,82]
Develops encephalitis 0.005 0.002–0.009 [29,31,42]
Develops chronic neurologic sequelae 0.33 0.25–0.50 [32,33]
CHILD
Intervention GI adverse event with erythromycin 0.34 0.27–0.44 [13,19,28]
GI adverse event with azithromycin 0.19 0.12–0.20 [18]
GI adverse event with clarithromycin 0.32 0.20–0.402 [19]
Pertussis Acquires pertussis post-exposure 0.061 0.048–0.440 [13,28]
Develops moderate to severe respiratory pertussis 0.25 0.10–0.32 [42,83]
Hospitalization for severe disease 0.07 0.04–0.08 [29,30,58]
Death 0.0006 0.0004–0.0010 [29,30,70]
Develops encephalitis/ encephalopathy 0.0008 0.0005–0.0040 [29,30,32]
Develops chronic neurologic sequelae 0.33 0.25–0.50 [1,32,33]
ADULT
Intervention GI adverse event with erythromycin 0.34 0.27–0.44 [13,19,28]
GI adverse event with azithromycin 0.19 0.12–0.20 [18]
GI adverse event with clarithromycin 0.32 0.2–0.402 [19]
Pertussis Acquires pertussis post-exposure 0.061 0.048–0.200 [13,68]
Develops moderate to severe respiratory pertussis 0.035 0.021–0.040 [29,30]
Hospitalization for severe disease 0.027 0.008–0.060 [28,30,73]
Death 0.0001 0–0.0010 [29,30,75]
Develops encephalitis/ encephalopathy 0.0005 0.0002–0.0040 [29,30,32]
Develops chronic neurologic sequelae 0.33 0.25–0.50 [32,33]
1 Assumption based on 2 case reports of azithromycin-associated IHPS [36]
2 Assumption of range
GI: gastrointestinal
IHPS: infantile hypertrophic pyloric stenosis
PEP: post-exposure prophylaxis
doi:10.1371/journal.pone.0119271.t001
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Health outcomes. QALYs combine quality of life and duration of life, or life years, into a
single measure. Health states were valued with preferences (Table 2) drawn from individuals
with pertussis [38]. In this study, time trade-off and contingent valuation methods were used
to determine utilities of short-term health states among adult patients and parents of adoles-
cent patients diagnosed with pertussis [38]. Infant utilities were derived from the adult respon-
dents, who were presented with the scenario of a 1-month old who developed pertussis, and
asked to value the prevention of short-term health states, that is respiratory or neurologic com-
plications lasting 8 weeks’ duration, as compared to long-term health states, which reflect neu-
rologic sequelae [38].
The time spent in each health state was derived from studies examining the natural course
of pertussis in under-immunized populations [39–43], and was multiplied by the correspond-
ing preference value to calculate the QALYs. The literature search did not identify a study re-
porting a preference value for IHPS, and so it was assumed to be the same as for encephalitis
without sequelae, given the need for hospitalization and short-term disability.
Table 2. Utility values and duration of relevant health states.
Health State Utility value for base case (SD) Days in ﬁrst year Reference (utility; duration)
INFANT
Mild illness, outpatient 0.67 (0.30) 76 [40,41]
Hospitalization 0.58 (0.37) 8 [38,39]
Respiratory complications 0.58 (0.37) 8 [38]
Encephalitis without sequelae 0.51 (0.38) 14 [38]
Chronic neurologic sequelae1 0.77 (0.25)2 365 [38]
IHPS 0.51 (0.38)3 6 Assumption; [34,43]
CHILD
Mild cough, outpatient 0.85 (0.26)4 76 [38,41]
Moderate-severe cough, outpatient 0.81 (0.30) 76 [38,41]
Hospitalization with recovery 0.67 (0.33) 3 [38,42]
Encephalitis without sequelae 0.51 (0.38) 14 [38]; Assumption
Chronic neurologic sequelae 0.77 (0.25) 365 [38]; Assumption
GI adverse event 0.70 (0.15)5 7 [84]; Assumption
ADULT
Mild cough 0.85 (0.26) 87 [38,40]
Moderate cough 0.81 (0.30) 87 [38,40]
Hospitalization for respiratory complications 0.62 (0.40) 3 [38,42]
Encephalitis without sequelae 0.51 (0.38) 14 [38]; Assumption
Chronic neurologic sequelae 0.77 (0.25) 365 [38]; Assumption
GI adverse event 0.70 (0.15)5 7 [84]; Assumption
1 Utility value and duration in health state assumed to be the same for all age groups
2 Interpreted as willing to give up 84 days of life to prevent 1 year of neurologic sequelae
3 Assumed to be same as for encephalitis
4 Interpreted as willing to give up 8 days of life to prevent 8 weeks of mild cough that does not require hospitalization
5 Standard error
GI: gastrointestinal
IHPS: infantile hypertrophic pyloric stenosis
PEP: post-exposure prophylaxis
doi:10.1371/journal.pone.0119271.t002
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Costs. The direct medical costs were expressed in 2012 Canadian dollars, and were
associated with exposure to and treatment of pertussis. These costs include contact tracing by a
public health nurse to review the need for PEP within households, medications, GP visits, diag-
nostic testing, hospitalization and long-term medical costs associated with neurologic sequelae.
While there is no universal drug coverage in Ontario, medication costs were included in this
analysis as Canadian public health policy makers have recommended that prophylaxis, where
appropriate, should be supplied by public health [15]. Cost estimates are summarized in
Table 3. Costs of health care visits and procedures were obtained from the Ontario Health In-
surance Plan Schedule of Benefits [44], and prices for generic formulations from the Ontario
Drug Benefit Formulary [37,45].
The doses and dispensing costs for each macrolide are outlined in Table 4. Given the infant
contact is at highest risk for complications with pertussis in the first 4 months of life [9,46], the
model assumed a 6-week old infant whose weight was at the 50th percentile-for-age, or 5 kg, as
per the CDC Growth Charts for the United States [47]. Thus, the cost of erythromycin was
$2 and azithromycin $8.90. Similarly, a child was assumed to have completed the primary im-
munization series and prefer taking liquid preparations of antibiotics, so that a 10-year old
child whose weight was at the 50th percentile-for-age at 34 kg had erythromycin at a cost of
$13.58, azithromycin at $42.87 and clarithromycin at $8.16. An adult was assumed to be
30 years old and weigh 70 kg, so that erythromycin cost $10.24, azithromycin $7.84 and clari-
thromycin $11.54, respectively. The duration of prophylaxis and treatment of pertussis was as
per Health Canada guidelines [15].
Medications, GP visits and diagnostic testing are set by the Ministry for all practitioners and
pharmacies. Older children and adults with PEP-related gastrointestinal symptoms were as-
sumed to visit their GP to discuss discontinuation of therapy. Acquiring the disease incurred
further costs.
Hospitalization costs for pertussis and encephalitis were drawn from the Ontario Case Cost-
ing Initiative (OCCI), which collects case costing data for acute inpatient, day surgery and am-
bulatory care cases, complex continuing care and community care cases [39]. The mean cost
per hospitalized case includes costs associated with ward and intensive care, and diagnostic
and therapeutic resources. During the fiscal year 2010–2011, there were 10 pertussis-related
hospitalizations and fewer than 5 associated encephalitis cases. Fifty-one cases of encephalitis
associated with other infectious etiologies were reported to the OCCI and those costs were re-
viewed. Physician costs are not part of the OCCI, but an estimate of 5% of hospitalization costs
was used based on previous studies of influenza analyzing health administrative data (expert
opinion, based on [48,49]).
There are no data on long-term outcomes of patients with pertussis encephalitis. Direct
medical costs associated with the long-term neurologic sequelae of pertussis encephalitis were
extrapolated from a review of direct medical costs for children with complex medical condi-
tions in Ontario. Excluding initial hospitalization costs, the average costs of care for a child
with neurological impairment and technology assistance (including cerebrospinal fluid ventric-
ular shunt, gastrostomy, or tracheostomy) was $34,574 (interquartile range: $10,178-$97,063)
over a 2-year period [50]. This population was comparable with respect to burden of disease
and resource utilization patterns.
Analysis
Base case analysis was conducted for a previously healthy 6-week old infant at 5 kg; 10-year old
child at 34 kg; and 30-year old adult [51,52]. Deterministic sensitivity analysis was performed
to explore uncertainty in the point estimates, and a threshold analysis was performed for PEP
Pertussis Post-Exposure Prophylaxis: A Decision Model
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effectiveness. The ranges examined in the deterministic sensitivity analysis were derived either
from the confidence intervals of the point estimate used for the base case; or, if not available,
minimum and maximum values in the model were derived from point estimates in other ob-
servational studies (Table 1). Probabilistic sensitivity analysis was performed to address uncer-
tainty involving parameters with an underlying probability distribution, varying all selected
Table 3. Estimated direct medical costs per contact. Costs in Canadian dollars, 2012 valuation.
Parameter Base case value Standard Error Reference
GENERAL
Contact tracing (public health) 37.74 - Assumption1
Visit to GP 33.70 - [44]
Chest X-ray (professional and
technical cost)
32.65 - [44]
No pertussis 0 - Assumption
MEDICATIONS
Erythromycin2 Infant 2.00 - [45]
Child 13.58 - [37]
Adult 10.24 - [37]
Azithromycin3 Infant 8.90 - [37]
Child 42.87 - [37]
Adult 7.84 - [37]
Clarithromycin4 Child 8.16 - [37]
Adult 11.54 - [37]
PERTUSSIS
GI symptoms in child or adult contact 33.705 [44]
Outpatient with mild illness GP + treatment Assumption
Outpatient with moderate-severe
illness
2 GP visits + 1 chest x-ray + treatment Assumption
Hospitalization6 12,160 5,689 [39]
IHPS 10,340 550 [43]
COMPLICATIONS
Encephalitis 27,643 8370 [39]
Chronic neurologic sequelae7 103,652 148,867 [50]
1 Public health nurse with 4 years of seniority paid an hourly rate of CAD 37.74 (personal communication, Public Health Ontario, July 2012)
2 erythromycin at 40 mg/kg/day divided thrice daily for 7 days, maximum 200 mg/day; dispensed at $0.0713 per 50mg/mL and $0.1828 per 250 mg tablet;
cost is for 5-kg infant, 34-kg child, and adult contact
3 azithromycin at 10 mg/kg on Day 1 followed by 5 mg/kg once daily for 4 days, maximum 500 mg on Day 1 followed by 250 mg for 4 days; dispensed at
$5.9347 per 100mg/5mL and $1.3070 per 250mg tablet
4 clarithromycin at 15 mg/kg/day divided twice daily, maximum 1000g/day, dispensed for a child at $0.5712 per 250mg/5mL; and an adult at $0.4122 per
250mg tablet
5 Cost of 1 GP visit for clinical assessment and antibiotic prescription
6 Hospitalization includes the infant with an uncomplicated admission; infant with respiratory complications; child and adult hospitalizations; death in
all groups
7 Mean cost and standard deviation over 2-year period; includes initial hospitalization
GI: gastrointestinal
GP: general practitioner
IHPS: infantile hypertrophic pyloric stenosis
PEP: post-exposure prophylaxis
doi:10.1371/journal.pone.0119271.t003
Pertussis Post-Exposure Prophylaxis: A Decision Model
PLOS ONE | DOI:10.1371/journal.pone.0119271 March 6, 2015 8 / 17
variables simultaneously [53]. In this assessment, beta distributions for probabilities and utili-
ties and gamma distributions for costs were derived, based on mean and standard error [54].
The model was run 10,000 times so that each event of interest may occur at least once in the
simulation. Results were summarized as cost-effectiveness acceptability curves.
Results
From the model, PEP with azithromycin prevents 439 secondary cases per 1,000 infant con-
tacts, and 41 secondary cases per 1,000 child and adult contacts. The results for the base case
analysis are shown in Table 5. A previously-healthy 5-kg infant contact who did not receive
PEP experienced 19.22 QALYs, whereas a macrolide resulted in at least 0.45 more expected
QALYs, or 165 quality-adjusted life days. Between the macrolides, azithromycin dominated
erythromycin with lower expected costs ($1,976 versus $2,096) and outcomes (19.6661 versus
19.6660 QALYs). These findings were sensitive to costs of hospitalization, costs of encephalitis
and probability of hospitalization, death, PEP effectiveness and acquiring disease following ex-
posure, and not sensitive to the probability of complications, death, annual costs of neurologic
sequelae, probability of an IHPS event with either macrolide, and changes in utility on PEP or
with any pertussis health state. However, in all scenarios in univariate and probabilistic sensi-
tivity analyses, azithromycin dominated erythromycin and no PEP.
Table 4. Macrolide strategies for pertussis PEP among household contacts.
Strategy Dose (oral) Cost Duration
(days)
Erythromycin 40 mg/kg/day divided three times daily (maximum 2,000 mg/day) $0.0713 per 50 mg/mL and $0.1828 per 250
mg tablet
7
Azithromycin 10 mg/kg (maximum 500 mg) on day 1 followed by 5 mg/kg (maximum
250 mg) once daily
$5.9347 per 100mg/5mL and $1.3070 per
250mg tablet
5
Clarithromycin1 15 mg/kg/day divided twice daily (maximum 1,000 mg/day) $0.5712 per 250mg/5mL and $0.4122 per
250mg tablet
7
1 Not included as strategy among infants
doi:10.1371/journal.pone.0119271.t004
Table 5. Costs, effects and cost-effectiveness of prophylaxis with erythromycin, azithromycin or clarithromycin compared with no intervention
for household contacts of cases of pertussis, stratiﬁed by age group, discounted at 5%.
Age
group
Strategy Average expected cost
($)
Average expected
QALY
Difference in cost
($)
Difference in
QALY
ICER ($ per
QALY)
Infant azithromycin 1,975.87 19.66612 - -
erythromycin 2,095.70 19.66602 - - dominated
none 5,815.10 19.21593 - - dominated
Child none 35.13 19.37751 - - -
clarithromycin 101.98 19.40780 66.86 0.0303 2,207
erythromycin 107.85 19.40753 - - dominated
azithromycin 132.04 19.40957 30.06 0.0018 16,963
Adult none 14.22 18.72856 - - -
azithromycin 90.25 18.76004 76.02 0.0315 2,415
erythromycin 97.74 18.75800 - - dominated
clarithromycin 98.37 18.75827 - - dominated
doi:10.1371/journal.pone.0119271.t005
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The lifetime expected health outcomes for a previously healthy 10-year-old contact were
19.38 QALYs without intervention and increased by 12 days (0.032 QALYs) with azithromycin
PEP, with a $97 cost increase for an ICER of $16,963 per QALY when compared with clarithro-
mycin. While clarithromycin was less expensive than azithromycin, there were fewer QALYs
gained, thus making it the non-preferred option in the base case scenario and sensitivity analy-
ses. In the probabilistic sensitivity analysis, the median ICER of azithromycin compared to
clarithromycin was $16,709 per QALY (mean $16,966 per QALY, 95% CI: $16,900-$16,972 per
QALY), and was sensitive to the probability of a GI adverse event with clarithromycin and azi-
thromycin, the probability of acquiring disease, and PEP effectiveness, but not sensitive to the
complications and costs of pertussis, including probability and cost of hospitalization, the
probability and costs of encephalitis and its sequelae, probability of death, and changes in utili-
ty on PEP or with any pertussis health state (Fig. 2A). No PEP had a 95% probability of being
cost-effective when the willingness-to-pay threshold was below $2,000 per QALY, whereas azi-
thromycin had a 95% probability of being cost-effective at the threshold of $50,000 per QALY
(Fig. 3A).
Among adult contacts, the quality-adjusted life expectancy was 18.73 years without PEP.
Azithromycin was the dominant strategy compared to the other macrolides, with more QALYs
and lower costs. Compared to no intervention, which was the least costly option, PEP with azi-
thromycin resulted in an additional 0.031 QALYs, or 11 quality-adjusted life days, and $76 in
incremental costs, for an ICER of $2,415 per QALY. The median ICER was $2,574 per QALY
(mean $2,426 per QALY, 95% CI $2,425-$2,426 per QALY) and was sensitive to PEP effective-
ness, probability of acquiring disease and probability of encephalitis, and not sensitive to the
probability of an adverse GI event with azithromycin, sequelae and death, costs of hospitaliza-
tion and encephalitis, and changes in utility on PEP or with any pertussis health state; however,
azithromycin remained the preferred strategy (Fig. 2B). Among adult contacts, azithromycin
was the preferred strategy, with a 95% probability of being cost-effective at $4,000 per QALY
(Fig. 3B).
A threshold analysis for the effectiveness of PEP in preventing a secondary case of pertussis
is shown in Table 6. Among infants, when the PEP effect was 0.2% or greater, azithromycin of-
fered the highest net benefit of all strategies. Among children and adults, this threshold proba-
bility was 10% and 9%, respectively. Below these values, none of the macrolides offered a
higher net benefit than no post-exposure prophylaxis.
Discussion
A cost-utility analysis was undertaken to examine 4 strategies against pertussis transmission to
household contacts. The decision model synthesized evidence from a broad range of published
literature and used QALYs as a preference-based outcome measure. Azithromycin offered the
most QALYs in all age groups. Among infants, PEP with azithromycin had the lowest expected
cost and most QALYs. This strategy was cost-effective among children and adult contacts at
$16,963 and $2,415 per QALY gained, respectively, compared to no PEP, which was well under
the cost-effectiveness threshold of $50,000 per QALY gained. The findings were robust in sen-
sitivity analyses. In particular, when the probability of disease acquisition and disease severity
were minimized (reflecting an immune population), disease-related costs were still significant,
especially among infants, and azithromycin remained the preferred strategy.
Pertussis transmission has been mitigated historically through immunization and chemo-
prophylaxis. While numerous studies have analyzed the impact of varying immunization strat-
egies [32,38,40,55–60], this is the first study to comparatively evaluate the benefits, risks and
costs associated with antibiotic PEP options among household contacts.
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A recent systematic review found only 2 RCTs related to pertussis PEP [13,61], and insuffi-
cient evidence to support erythromycin for all household contacts [62]; although, they may not
have been sufficiently powered to detect a significant difference. An argument against PEP is
that widespread immunization has been associated with a milder clinical course among sec-
ondary cases [41,63–65]. Most chemoprophylaxis studies occurred in the context of an under-
immunized adult population [3,5,66,67] and large cohort studies have demonstrated some ben-
efit in offering PEP to household contacts [27,28,68,69]. However, a recent study among a
highly-immunized population of health care professionals found no difference in rates of
symptomatic pertussis between those who received PEP compared to daily symptom monitor-
ing [64]. The authors questioned whether antibiotic PEP could be eliminated in such popula-
tions, given the potential for reduced prescriptions, rates of adverse events, and labor costs
Fig 2. Tornado diagram of the univariate sensitivity analysis for the azithromycin PEP strategy for child (A) and adult (B) contacts. Azithromycin
remained the dominant strategy among infants. The bars represent the variation in cost-effectiveness ratios from the base case scenario in response to
sequential changes in model parameters, with the vertical axis reflecting the base case ICER. The maximal and minimal values were tested according to
ranges outlined in Table 1. (A) Axis at $16,963 per QALY. (C) Axis at $2,415 per QALY.
doi:10.1371/journal.pone.0119271.g002
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associated with contact tracing, evaluation and counseling for PEP. However, all participants
had been immunized against pertussis within the previous 2 years, suggesting higher rates of
immunity than what may be found in the general community [67]. Thus, the marginal benefits
of PEP in this study may have been smaller compared to what may be found in the general
population, particularly among infants and young children who are at highest risk for severe
disease [29,42,66].
The analysis has several limitations. The model does not account for changes in disease inci-
dence as it is not an infectious disease transmission model; however the probability of acquir-
ing pertussis and the impact of prophylaxis were varied in sensitivity analyses. The healthcare
payer perspective includes only direct medical costs related to health care resource utilization,
such as medication, laboratory, procedures and personnel, hospitalizations and physician visits
[55]. Numerous studies have highlighted the significant indirect medical and non-medical
costs of pertussis [32,40,59,60,70–75]. Given that the antibiotic strategies had similar effective-
ness, the differences in non-medical costs between each regimen may be minimal. However,
the indirect economic benefit of PEP in avoiding pertussis and its complications may have
been underestimated, as the model did not account for QALY loss of caregivers looking after
contacts with pertussis or with neurologic sequelae following pertussis encephalitis.
Fig 3. Cost-effectiveness acceptability curves for child (A) and adult (B) contacts. These curves reflect the proportion of times each intervention is likely
to be cost-effective for a given cost-effectiveness threshold, up to $50,000 per additional QALY. Clarithromycin post-exposure prophylaxis was never a
preferred strategy for adult contacts, and so does not feature for clarity.
doi:10.1371/journal.pone.0119271.g003
Table 6. Threshold analysis of post-exposure prophylaxis effectiveness.
PEP effect
Contact Group 0 0.001 0.002 0.005 0.01 0.08 0.09 0.1 0.9 1
Infant no no A A A A A A A A
Child no no no no no no no A A A
Adult no no no no no no A A A A
“no” indicates no PEP as the preferred option.
“A” indicates azithromycin. When PEP has zero effect, the net beneﬁt of no prophylaxis exceeds that of azithromycin and other macrolides. At or above
10% effectiveness, PEP with azithromycin offers a higher net beneﬁt than no intervention.
doi:10.1371/journal.pone.0119271.t006
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The costs incurred during lifeyears gained from the intervention were not included in this
model, in keeping with Canadian guidelines on economic evaluations [20]. Whether to include
future unrelated healthcare costs, that is costs solely due to changes in survival, has been con-
troversial. Theoretical arguments for [76] and against inclusion [77] of unrelated costs have
been advanced and debated [78].To date no consensus has been reached, and to the best of our
knowledge, no current guideline on economic evaluation calls for inclusion of unrelated cost as
a requirement. The Canadian guideline recommends including unrelated costs only in sensitiv-
ity analysis, if at all [20]. While substantial survival benefits may have a major impact on
spending, in the case of pertussis, where the highest risk of mortality is among infants and at
0.6%, offering chemoprophylaxis arguably does not have substantial effects on survival. Since
these costs were excluded, the cost-effectiveness of the intervention was likely overestimated.
Existing clinical and cost data were applied to each age group used in this model, and so nu-
merous assumptions were made regarding the calculation and application of costs and proba-
bilities where published data were not available. It is arguable that the populations from which
secondary attack rates are estimated may differ from the best available data, which is from Que-
bec during the 1990s. Despite subsequent changes in the immunization schedules, including a
booster dose during adolescence and among adults in contact with children, and in vaccine
product, from an adsorbed whole cell vaccine to acellular vaccine, there is no prospective sur-
veillance on immunization rates or household secondary attack rates. Moreover, more than
half of pertussis cases continue to occur among children and adults reported as being fully im-
munized for their age [7,9,28,79], and an increasing lack of protection has been found among
children within 5 years of completing the childhood immunization series against pertussis
[11]. In this economic analysis, to explore the uncertainty in secondary attack rates, the proba-
bility of acquiring disease was varied broadly, and did not result in a change in the preferred
strategy for contacts in any of the age groups.
The assumption that respiratory and neurologic diseases are mutually exclusive does not
necessarily reflect clinical experience; however the associated costs and QALYs of both compli-
cations are likely to overlap, and thus be potentially overestimated in this analysis. The utility
scores for infants were derived from adolescent and adult respondents, which may have im-
pacted the validity of the QALYs measured. Direct elicitation of preferences can be especially
challenging in children due to evolving developmental maturity and their cognitive abilities at
various ages to value health; parents may also not reliably report on subjective outcomes of
clinical conditions, all of which potentially impact the validity and generalizability of the
QALYs measured.[80,81] Furthermore, only respiratory and neurologic complications were in-
cluded, while other serious health states in the disease spectrum were not assessed, including
apneic spells with spontaneous and complete recovery, generalized illness with outpatient care,
and long-term neurologic sequelae following encephalitis.
All cases reported to the OCCI were less than 18 years of age, and the costs of encephalitis
and long-term neurologic sequelae have been extrapolated from other disease processes. The
cost of death was the same as for hospitalization in this model; however end-of-life care is asso-
ciated with higher costs [46,49]. Uncertainty in the parameter estimates was tested through
univariate and probabilistic sensitivity analyses, and did not shift the preferred strategy from
the base case scenario.
Alongside policy recommendations for immunization of infants, children, adolescents and
adults, there remains an important role for chemoprophylaxis in the prevention of pertussis,
especially in outbreaks, when immunization is not immediately protective, and among infants,
who are at highest risk for complicated disease. Our analysis suggests azithromycin PEP to be
cost-effective when compared with other macrolides and no intervention, protecting house-
hold contacts from acquiring infection at acceptable costs.
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